Cambridge Cognition Holdings PLC Directorate Change (8214U)
03 Agosto 2022 - 3:55PM
UK Regulatory
TIDMCOG
RNS Number : 8214U
Cambridge Cognition Holdings PLC
03 August 2022
3 August 2022
Cambridge Cognition Holdings Plc
("Cambridge Cognition", the "Company" or the "Group")
Directorate Change
Cambridge Cognition Holdings Plc (AIM: COG), which develops and
markets digital solutions to assess brain health, is pleased to
announce that further to the announcement of 6 April 2022, Stephen
Symonds, Chief Financial Officer, has been appointed to the Board
of Cambridge Cognition as an Executive Director with immediate
effect.
Stephen was previously the CFO of Envigo, a provider of
pre-clinical services to the pharmaceutical industry, where he
spent eight years. Prior to that, Stephen spent a decade with KPMG,
working on a wide-ranging portfolio of clients.
Steven Powell, Chairman of the Company, commented: "We are
delighted that Stephen is joining the Board. He has extensive
relevant experience and has fitted in very well with the team since
joining the Company in April this year."
Additional Information in respect of the AIM Rules
The following information regarding the appointment of Stephen
Daniel Symonds, aged 47, is disclosed under Schedule Two paragraph
(g) of the AIM Rules for Companies:
Current Directorships Previous Directorships (within the
last five years)
Centralabs Clinical Research Limited
----------------------------------------
Covance Consulting Limited
----------------------------------------
Covance CRS Analytics Limited
----------------------------------------
Covance CRS Developments Limited
----------------------------------------
Covance CRS International Limited
----------------------------------------
Covance Pharma Consulting Limited
----------------------------------------
Envigo CRS (Switzerland) Limited
----------------------------------------
Envigo CRS GmbH
----------------------------------------
Envigo CRS Israel Limited
----------------------------------------
Envigo CRS SA
----------------------------------------
Envigo CRS Switzerland Limited
----------------------------------------
Envigo Holdings Limited
----------------------------------------
Envigo Monitoring Limited
----------------------------------------
Envigo RMS (UK) Limited
----------------------------------------
Envigo RMS BV
----------------------------------------
Envigo RMS GmbH
----------------------------------------
Envigo RMS India Private Limited
----------------------------------------
Envigo RMS Israel Limited
----------------------------------------
Envigo RMS Sarl
----------------------------------------
Envigo RMS SL
----------------------------------------
Envigo RMS Srl
----------------------------------------
Envigo Ventures Limited
----------------------------------------
Harlan Eurasia Holdings Limited
----------------------------------------
Harlan Europe Holdings Limited
----------------------------------------
HIH Limited
----------------------------------------
Huntingdon Consulting Engineers Limited
----------------------------------------
Huntingdon Research Centre Limited
----------------------------------------
Labcorp Research Limited
----------------------------------------
Labcorp UK Limited
----------------------------------------
Paragon Global Services Limited
----------------------------------------
Pathfinder Clinical Development Limited
----------------------------------------
Pathfinder Nominees Limited
----------------------------------------
Servicepharm Limited
----------------------------------------
As at the date of this announcement, Stephen Symonds holds
22,950 ordinary shares in the Company representing 0.07% of the
Company's issued share capital. In addition, Stephen holds an
interest in 152,671 options over ordinary shares of the
Company.
Save as set out above there are no further disclosures pursuant
to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for
Companies in respect of the appointment of Stephen Symonds.
For further information, please contact:
Cambridge Cognition Holdings Plc Tel: 01223 810 700
Matthew Stork, Chief Executive Officer press@camcog.com
Stephen Symonds, Chief Financial Officer
Panmure Gordon (UK) Ltd
(NOMAD and Joint Broker) Tel: 020 78862500
Freddy Crossley / Emma Earl / Mark (Corporate Advisory)
Rodgers
Rupert Dearden (Corporate Broking)
Dowgate Capital Limited (Joint Broker) Tel: 020 3903 7715
David Poutney / James Serjeant
IFC Advisory Ltd (Financial PR and Tel: 020 3934 6630
IR)
Tim Metcalfe / Graham Herring / Zach cog@investor-focus.co.uk
Cohen
Notes to Editors
About Cambridge Cognition
Cambridge Cognition is a technology company developing digital
health products to better understand, detect and treat conditions
affecting brain health. The Company's software products assess
cognitive health in patients worldwide to improve clinical trial
outcomes, identify and stratify patients early and improve global
efficiency in pharmaceutical and healthcare industries.
For further information visit www.cambridgecognition.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAKZGGRFFMGZZM
(END) Dow Jones Newswires
August 03, 2022 09:55 ET (13:55 GMT)
Grafico Azioni Cambridge Cognition (AQSE:COG.GB)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Cambridge Cognition (AQSE:COG.GB)
Storico
Da Dic 2023 a Dic 2024
